# Phase II Trial of Neoadjuvant and Adjuvant IO102-IO103 and Pembrolizumab KEYTRUDA® in Patients With Resectable Tumors

Source: https://onco.cc/trials/nct05280314/  
OnCo record `nct05280314` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of IO102-IO103 in melanoma, run by IO Biotech, now recruiting.

## Summary

Phase II Trial of Neoadjuvant and Adjuvant IO102-IO103 and Pembrolizumab KEYTRUDA® in Patients With Resectable Tumors is a phase 2 interventional study registered as NCT05280314 by IO Biotech, with 60 participants planned, started 2023-12-21 and due to reach its primary completion in 2025-04-30. Interventions recorded: IO102-IO103, Pembrolizumab KEYTRUDA®. Conditions listed: Melanoma, Squamous Cell Carcinoma of Head and Neck. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT05280314
- Phase: 2
- Setting: Phase II, Multi-cohort Trial of Neoadjuvant and Post-surgery IO102-IO103 and Pembrolizumab KEYTRUDA® in Patients With Selected Resectable Tumors
- Sponsor: IO Biotech
- Enrolled: 60

## Sources

- ClinicalTrials.gov NCT05280314: https://clinicaltrials.gov/study/NCT05280314

## Connected records

- cancers: [Melanoma](https://onco.cc/cancers/melanoma/)
- drugs: [IO102-IO103](https://onco.cc/drugs/io102-io103/)
- companies: [IO Biotech](https://onco.cc/companies/io-biotech/)

---
JSON: https://onco.cc/api/v1/entities/nct05280314.json